Mary Slavcev

Teclistamab Plus Daratumumab Versus Standard Daratumumab-Based Proteasome Inhibitor Combinations for Relapsed/Refractory Multiple Myeloma: An Inverse Probability of Treatment Weighting Analysis

In the phase 3 MajesTEC-3 study (NCT05083169), teclistamab with daratumumab (Tec-Dara) significantly improved progression-free and overall survival (PFS/OS) versus investigator’s choice of standard-of-care daratumumab/pomalidomide/dexamethasone (DPd) or daratumumab/bortezomib/dex...